BG107093A - Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер - Google Patents

Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер Download PDF

Info

Publication number
BG107093A
BG107093A BG107093A BG10709302A BG107093A BG 107093 A BG107093 A BG 107093A BG 107093 A BG107093 A BG 107093A BG 10709302 A BG10709302 A BG 10709302A BG 107093 A BG107093 A BG 107093A
Authority
BG
Bulgaria
Prior art keywords
day
dose
galantamine
dosage
treatment
Prior art date
Application number
BG107093A
Other languages
Bulgarian (bg)
English (en)
Inventor
Wim Louis PARYS
Michael Pontecorvo
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG107093A publication Critical patent/BG107093A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
BG107093A 2000-04-03 2002-09-12 Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер BG107093A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (fr) 2000-04-03 2001-03-28 Utilisation de la galantamine dans le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
BG107093A true BG107093A (bg) 2003-06-30

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107093A BG107093A (bg) 2000-04-03 2002-09-12 Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер

Country Status (20)

Country Link
EP (1) EP1272192A2 (fr)
JP (1) JP2003528913A (fr)
KR (1) KR20020086911A (fr)
CN (1) CN1430514A (fr)
AU (2) AU2001265844B2 (fr)
BG (1) BG107093A (fr)
BR (1) BR0109770A (fr)
CA (1) CA2310926C (fr)
CZ (1) CZ20023543A3 (fr)
EE (1) EE200200554A (fr)
HR (1) HRP20020778A2 (fr)
HU (1) HUP0300566A3 (fr)
IL (1) IL152061A0 (fr)
MX (1) MXPA02009777A (fr)
NO (1) NO20024746L (fr)
PL (1) PL361272A1 (fr)
RU (1) RU2002129298A (fr)
SK (1) SK15422002A3 (fr)
WO (1) WO2001074339A2 (fr)
ZA (1) ZA200207935B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
ES2293287T3 (es) 2003-07-25 2008-03-16 F. Hoffmann-La Roche Ag Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
AU2009229372C1 (en) 2008-03-27 2017-02-02 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2013160728A1 (fr) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Composés à double ciblage pour le traitement de la maladie d'alzheimer
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
AU2016264228B2 (en) * 2015-05-18 2019-06-13 Synaptec Development Llc Galantamine clearance of amyloidß
WO2023036105A1 (fr) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 Méthode de traitement d'une maladie neurodégénérative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en) * 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310950C (fr) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. Posologie de galantamine efficace qui reduit les effets secondaires
CA2310990A1 (fr) * 2000-04-03 2000-10-09 Michael Pontecorvo Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie

Also Published As

Publication number Publication date
RU2002129298A (ru) 2004-03-27
KR20020086911A (ko) 2002-11-20
HUP0300566A2 (hu) 2003-06-28
PL361272A1 (en) 2004-10-04
AU6584401A (en) 2001-10-15
WO2001074339A3 (fr) 2002-09-12
HUP0300566A3 (en) 2004-10-28
WO2001074339A2 (fr) 2001-10-11
NO20024746D0 (no) 2002-10-02
NO20024746L (no) 2002-11-28
CA2310926A1 (fr) 2000-10-04
AU2001265844B2 (en) 2005-04-14
SK15422002A3 (sk) 2003-04-01
CZ20023543A3 (cs) 2003-03-12
BR0109770A (pt) 2003-02-04
ZA200207935B (en) 2004-01-30
EE200200554A (et) 2004-04-15
MXPA02009777A (es) 2003-03-27
HRP20020778A2 (en) 2004-04-30
EP1272192A2 (fr) 2003-01-08
IL152061A0 (en) 2003-05-29
CN1430514A (zh) 2003-07-16
JP2003528913A (ja) 2003-09-30
CA2310926C (fr) 2002-10-15

Similar Documents

Publication Publication Date Title
US20210283094A1 (en) Combination therapy using low-dose doxepin for the improvement of sleep
BG65474B1 (bg) Използване на рамиприл за профилактика на кардиоваскуларни смущения
US20240366582A1 (en) Treatment of raynaud's disease
US20030139391A1 (en) Efficacious dosage regimen of galantamine that reduces side effects
BG107093A (bg) Приложение на галантамин за лечение на невропсихиатрични разстройства в поведението, свързани с болестта на алцхаймер
KR20020075797A (ko) 엔도텔린 유발성 질환 치료제
Bachert et al. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis
AU2001265844A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
US20240148709A1 (en) Methods of treating eye pain and eye disorders
US12023315B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
US20060172993A1 (en) Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease
WO2020014072A1 (fr) Association pharmaceutique de néostigmine pour le traitement de la myasthénie grave
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
US20240398771A1 (en) Treatment of scleroderma and raynaud's syndrome
US20240358693A1 (en) Methods of treating pain
CA2310990A1 (fr) Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie
EP3691668A1 (fr) Traitement contre la dépression réfractaire aux autres thérapies